Abstract: We learn in everyday life that data is created and marketed at a rate that could not be seen a few years back. At present, when data is increasing exponentially over the successfully opened ...

Others suggest their work is “paradigm changing” and go on to describe how they prove their hypothesis. Naturally, such bold claims capture our attention, but unfortunately, more often than ...

The company's paediatric phase 3 PARADIGMS study met its primary endpoint, showing a significant reduction in relapses in patients treated with Gilenya (fingolimod) versus Biogen’s Avonex ...